Zibotentan in combination with dapagliflozin compared with dapagliflozin in patients with chronic kidney disease (ZENITH-CKD): a multicentre, randomised, active-controlled, phase 2b, clinical trial
Clinical manifestations may involve multiple systems, including neurological, gastrointestinal, and musculoskeletal domains
This flat rate means your maintenance dosewhether 5 mg, 10 mg, or 15 mgcosts the same
In this context, the glucagon-like peptide-1 (GLP-1) receptor system has emerged as a paradigm-shifting model ( 3 GLP-1 receptor signaling and GLP-1RA in metabolic disorders The global prevalence of metabolic dysfunction, encompassing obesity and T2DM, has reached pandemic proportions (Rohm et al., 2022), and organelle dysfunction (Lemmer et al., 2021)